VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2019 | Cami-T: promising results in classical Hodgkin lymphoma

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the trial of camidanlumab tesirine (ADCT-301, Cami-T), an antibody-drug conjugate that binds to CD25, in relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter